SEC Form SC 13G/A filed

2/12/21 12:27:54 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $IDXX alert in real time by email

SC 13G/A 1 fundsmith_idexx2020.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1 Name of Issuer: IDEXX LABORATORIES INC Title of Class of Securities: Common Stock CUSIP Number: 45168D104 (Date of Event Which Requires Filing of this Statement) December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-l(b) / / Rule 13d-l(c) / / Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 45168D104 1. Name of Reporting Person Fundsmith LLP 2. Check the Appropriate Box if a Member of a Group a. / / b. / / 3. SEC Use Only 4. Citizenship or Place of Organization United Kingdom Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 4,208,427 6. Shared Voting Power: NONE 7. Sole Dispositive Power: 4,226,428 8. Shared Dispositive Power: NONE 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,226,428 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9) 4.95% 12. Type of Reporting Person IA -2- Item 1(a) Name of Issuer: IDEXX LABORATORIES INC (b) Address of Issuer's Principal Executive Offices: One IDEXX Drive, Westbrook, ME 04092, United States Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: Fundsmith LLP 33 Cavendish Square, London, UK, W1G 0PQ (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 45168D104 Item 3. This statement is filed pursuant to Rule 13d-1(b)(1). / / Broker or Dealer registered under Section 15 of the Act. /x/ An investment adviser in accordance with Rule 13d-1(b)(1) (ii)(E) Item 4. Ownership. (a) Amount Beneficially Owned: 4,226,428 (b) Percent of Class: 4.95% (c) (i) shares with sole power to vote or direct the vote: 4,208,427 (ii) shared power to vote or direct the vote: NONE (iii) shares with sole power to dispose or to direct the disposition of: 4,226,428 (iv) shares with shared power to dispose or direct the disposition of: NONE Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following /x/. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A -3- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of the Group. N/A Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. By: /s/ Simon Godwin February 12, 2021 _________________________ _________________ Title: Chief Financial Officer Date

Get the next $IDXX alert in real time by email

Recent Analyst Ratings for

$IDXX

Date	Price Target	Rating	Analyst
12/2/2024	$500.00	Outperform	Leerink Partners
7/25/2024	$580.00	Buy	BTIG Research
1/30/2024	$525.00	Overweight → Neutral	Piper Sandler
12/7/2023	$602.00	Outperform	Exane BNP Paribas
12/4/2023		Neutral → Buy	Cleveland Research
8/2/2023	$610.00	Overweight → Neutral	Atlantic Equities
7/25/2022	$415.00	Buy → Hold	Stifel
7/21/2022	$530.00 → $435.00	Neutral → Buy	Goldman

More analyst ratings

SEC Form SC 13G/A filed

Chat with this insight

Recent Analyst Ratings for
$IDXX

$IDXX
Financials

Live finance-specific insights

IDEXX Laboratories Announces First Quarter Results

IDEXX Laboratories to Release 2025 First Quarter Financial Results

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

$IDXX
SEC Filings

SEC Form 10-Q filed by IDEXX Laboratories Inc.

IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by IDEXX Laboratories Inc.

$IDXX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.